|
25.10.2024 07:57:47
|
Sanofi Q3 Profit Rises - Quick Facts
(RTTNews) - French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion euros up from 2.53 billion euros in the prior year. IFRS earnings per share rose to 2.25 euros from 2.01 euros in the previous year.
Quarterly business net income increased to 3.59 billion euros from 3.20 billion euros in the prior year.
Business earnings per share was 2.86 euros, an increase of 12.2% on a reported basis or increase 17.6% at constant exchange rates or CER.
Net sales for the third quarter rose to 13.44 billion euros from 11.96 billion euros in the prior year.
On October 21, 2024, the 2024 business earnings per share guidance was upgraded to growth of at least a low single-digit percentage at CER supported by the underlying strong business performance. This reflects the new scope of guidance excluding Opella.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sanofi S.A. (spons. ADRs)
|
13.04.26 |
Aktien von Regeneron und Sanofi schwächer: Dupixent erhält weitere Zulassung in der EU (Dow Jones) | |
|
27.02.26 |
Sanofi-Aktie höher: Regeneron und Sanofi bekommen Empfehlung für erweiterte Dupixent-Zulassung (Dow Jones) | |
|
05.01.26 |
Sanofi-Aktie dennoch tiefer: Vorrangige FDA-Prüfung signalisiert Fortschritt für Kindertherapie (Dow Jones) | |
|
15.12.25 |
Sanofi-Aktie unter Druck: Zwei Rückschläge mit Tolebrutinib (finanzen.at) | |
|
25.11.25 |
Sanofi und Regeneron: Aktien nach Dupixent-EU-Zulassung stärker (Dow Jones) |
Analysen zu Sanofi S.A.
| 05.05.26 | Sanofi Neutral | JP Morgan Chase & Co. | |
| 28.04.26 | Sanofi Outperform | Bernstein Research | |
| 28.04.26 | Sanofi Buy | Deutsche Bank AG | |
| 27.04.26 | Sanofi Neutral | UBS AG | |
| 24.04.26 | Sanofi Neutral | UBS AG |
Aktien in diesem Artikel
| Sanofi S.A. (spons. ADRs) | 36,40 | -0,55% |
|
| Sanofi S.A. | 72,85 | -1,57% |
|